IMVT-1402

About Roivant Sciences

Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.

About Immunovant

Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.

About Immunovant

Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.

About Immunovant

Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.

About Immunovant

Immunovant is a clinical-stage biotech focused on developing and commercializing novel anti-FcRn antibodies to treat autoimmune diseases. Its lead assets, batoclimab and IMVT-1402, are designed to efficiently reduce pathogenic IgG autoantibodies via subcutaneous injection, offering potential advantages in safety, convenience, and dosing flexibility. The company's strategy leverages the Roivant ecosystem for capital efficiency and operational execution, aiming to capture significant value in the large and growing autoimmune therapeutics market.

Therapeutic Areas